Clinical Trial Update: AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating AK112 plus nab-paclitaxel versus placebo plus nab-paclitaxel as first-line treatment for inoperable locally advanced or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AK112
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Akeso | Conditions: Triple-Negative Breast Cancer (TNBC) | Phase 3 | Status: RECRUITING